Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Accelerating global innovation to address antibacterial resistance: introducing CARB-X.

Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J.

Nat Rev Drug Discov. 2016 Sep;15(9):589-590. doi: 10.1038/nrd.2016.155. Epub 2016 Jul 29.

PMID:
27469032
2.

Biocontainment laboratory risk assessment: perspectives and considerations.

Patterson A, Fennington K, Bayha R, Wax D, Hirschberg R, Boyd N, Kurilla M.

Pathog Dis. 2014 Jul;71(2):102-8. doi: 10.1111/2049-632X.12162. Epub 2014 Apr 4. Review.

PMID:
24591404
3.

High priority preparedness research and its support.

Coller-Monarez S, Groseclose SL, Kurilla MG, Berg JM.

J Public Health Manag Pract. 2013 Sep-Oct;19 Suppl 2:S9-11. doi: 10.1097/PHH.0b013e3182972287.

PMID:
23903401
4.

An automated solution for managing your workforce.

Wadsworth B, Kurilla ML.

Nurs Manage. 2009 Jun;40(6):49-51. doi: 10.1097/01.NUMA.0000356637.33834.00. No abstract available.

PMID:
19502932
5.

Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones.

Bobkova EV, Yan YP, Jordan DB, Kurilla MG, Pompliano DL.

J Biol Chem. 2003 Mar 14;278(11):9802-7.

6.

Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro.

Barbosa MD, Lin S, Markwalder JA, Mills JA, DeVito JA, Teleha CA, Garlapati V, Liu C, Thompson A, Trainor GL, Kurilla MG, Pompliano DL.

Antimicrob Agents Chemother. 2002 Nov;46(11):3549-54.

7.

A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis.

Barbosa MD, Ross HO, Hillman MC, Meade RP, Kurilla MG, Pompliano DL.

Anal Biochem. 2002 Jul 1;306(1):17-22.

PMID:
12069409
8.

Homogenous assays for Escherichia coli DnaB-stimulated DnaG primase and DnaB helicase and their use in screening for chemical inhibitors.

Zhang Y, Yang F, Kao YC, Kurilla MG, Pompliano DL, Dicker IB.

Anal Biochem. 2002 May 15;304(2):174-9.

PMID:
12009693
9.

PolC-type polymerase III of Streptococcus pyogenes and its use in screening for chemical inhibitors.

Yang F, Dicker IB, Kurilla MG, Pompliano DL.

Anal Biochem. 2002 May 1;304(1):110-6.

PMID:
11969194
10.

Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors.

Barbosa MD, Yang G, Fang J, Kurilla MG, Pompliano DL.

Antimicrob Agents Chemother. 2002 Apr;46(4):943-6.

11.

Oxazolidinones mechanism of action: inhibition of the first peptide bond formation.

Patel U, Yan YP, Hobbs FW Jr, Kaczmarczyk J, Slee AM, Pompliano DL, Kurilla MG, Bobkova EV.

J Biol Chem. 2001 Oct 5;276(40):37199-205. Epub 2001 Aug 1.

12.

A scintillation proximity assay for rna detection.

Liu J, Feldman PA, Lippy JS, Bobkova E, Kurilla MG, Chung TD.

Anal Biochem. 2001 Feb 15;289(2):239-45.

PMID:
11161317
13.
14.

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.

J Exp Med. 2000 May 15;191(10):1649-60.

15.

High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections.

Jin X, Demoitie MA, Donahoe SM, Ogg GS, Bonhoeffer S, Kakimoto WM, Gillespie G, Moss PA, Dyer W, Kurilla MG, Riddell SR, Downie J, Sullivan JS, McMichael AJ, Workman C, Nixon DF.

J Infect Dis. 2000 Jan;181(1):165-75.

PMID:
10608763
16.

Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.

Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM.

Eur J Immunol. 1999 Dec;29(12):3995-4001.

17.
18.
20.

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.

Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steigerwald-Mullen P, Kurilla MG, Frappier L, Rickinson A.

Immunity. 1997 Dec;7(6):791-802.

21.
23.

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.

Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB.

J Exp Med. 1997 May 5;185(9):1605-17.

25.

Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.

Frisan T, Zhang QJ, Levitskaya J, Coram M, Kurilla MG, Masucci MG.

Int J Cancer. 1996 Oct 9;68(2):251-8.

26.

Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.

White CA, Cross SM, Kurilla MG, Kerr BM, Schmidt C, Misko IS, Khanna R, Moss DJ.

Virology. 1996 May 15;219(2):489-92.

28.

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG.

Nature. 1995 Jun 22;375(6533):685-8.

PMID:
7540727
29.

A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame.

Kurilla MG, Heineman T, Davenport LC, Kieff E, Hutt-Fletcher LM.

Virology. 1995 May 10;209(1):108-21.

30.

Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.

Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, Doolan DL, Suhrbier A, Moss DJ, Kieff E, Sculley TB, Misko IS.

J Exp Med. 1994 Dec 1;180(6):2335-40.

31.

Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR.

J Virol. 1993 Dec;67(12):7623-8.

32.

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB.

J Virol. 1993 Dec;67(12):7428-35.

33.

Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.

Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB.

J Exp Med. 1993 Sep 1;178(3):879-87.

34.

Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG.

J Virol. 1993 Mar;67(3):1572-8.

35.

The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Lear AL, Rowe M, Kurilla MG, Lee S, Henderson S, Kieff E, Rickinson AB.

J Virol. 1992 Dec;66(12):7461-8.

36.

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ.

J Exp Med. 1992 Jul 1;176(1):169-76.

37.
38.
39.
40.

Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E.

J Virol. 1990 Jul;64(7):3407-16.

41.

Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.

Murray RJ, Kurilla MG, Griffin HM, Brooks JM, Mackett M, Arrand JR, Rowe M, Burrows SR, Moss DJ, Kieff E, et al.

Proc Natl Acad Sci U S A. 1990 Apr;87(8):2906-10.

43.

RNA sequence and transcriptional properties of the 3' end of the Newcastle disease virus genome.

Kurilla MG, Stone HO, Keene JD.

Virology. 1985 Sep;145(2):203-12.

PMID:
4024452
44.

Nucleotide sequence and host La protein interactions of rabies virus leader RNA.

Kurilla MG, Cabradilla CD, Holloway BP, Keene JD.

J Virol. 1984 Jun;50(3):773-8.

45.

Association between the 7 S RNA and the lupus La protein varies among cell types.

Chambers JC, Kurilla MG, Keene JD.

J Biol Chem. 1983 Oct 10;258(19):11438-41.

47.
48.

Rapid and transient localization of the leader RNA of vesicular stomatitis virus in the nuclei of infected cells.

Kurilla MG, Piwnica-Worms H, Keene JD.

Proc Natl Acad Sci U S A. 1982 Sep;79(17):5240-4.

49.

Congenital anomalies of the esophagus.

KURILLA MK.

Med Ann Dist Columbia. 1954 Nov;23(11):607-15. No abstract available.

PMID:
13213336

Supplemental Content

Loading ...
Support Center